Moleculin Biotech Reports 2025 Financials and Positive Pivotal AML Trial Progress with Mid-2026 Interim Data Unblinding
MBRX is trading near its 52-week low of $1.79 (12% above the low) on light trading volume (0.3× avg).
Summary
Moleculin Biotech reported full-year 2025 financial results, confirming a short cash runway into Q3 2026, but also announced encouraging preliminary clinical data from its pivotal MIRACLE trial for AML and confirmed the absence of cardiotoxicity for Annamycin, with key interim data unblinding expected mid-2026.
Key Events · Product Development and Regulatory · MBRX
-
Full Year 2025 Financial Results Reported
The company reported a net loss of $33.56 million for the year ended December 31, 2025.
-
Short Cash Runway Confirmed
Cash and cash equivalents of $8.9 million as of December 31, 2025, combined with $8.3 million from Q1 2026 financing, are projected to fund operations only into the third quarter of 2026.
-
Pivotal MIRACLE Trial Shows Encouraging Preliminary Data
The MIRACLE trial for relapsed/refractory AML reported a preliminary blinded composite complete remission (CRc) rate of 40% in the first 30 patients, including those with venetoclax failures.
-
Key Clinical Milestone Approaching
Interim data unblinding for 45 patients in the pivotal MIRACLE trial is on track for mid-2026, representing a significant upcoming catalyst.
Analysis · MBRX · Life Sciences
This filing provides the detailed financial results for 2025, confirming Moleculin Biotech's precarious financial position with a short cash runway into Q3 2026, as previously indicated in the recent 10-K. However, it also delivers significant positive clinical updates for its lead drug candidate, Annamycin. The encouraging preliminary blinded data from the pivotal MIRACLE trial for relapsed/refractory AML, showing a 40% composite complete remission (CRc) rate in a challenging patient population, coupled with the confirmed absence of cardiotoxicity, provides a strong counter-narrative. The upcoming mid-2026 unblinding of interim data for 45 patients represents a critical near-term catalyst that could significantly impact the company's future, potentially offsetting the severe financial challenges. Investors will be closely watching the MIRACLE trial's progress as the company seeks to secure additional financing.
At the time of this filing, MBRX was trading at $2.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $1.79 to $33.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.